Henan Taloph Pharmaceutical Stock Co Ltd Market Cap ($544.17 Million)
Market Cap & Net Worth: Henan Taloph Pharmaceutical Stock Co Ltd (600222)
Henan Taloph Pharmaceutical Stock Co Ltd market cap. Henan Taloph Pharmaceutical Stock Co Ltd (SHG:600222) has a market capitalization of $544.17 Million (CN¥3.72 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #11442 globally and #3214 in its home market, demonstrating a -0.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Henan Taloph Pharmaceutical Stock Co Ltd's stock price CN¥6.48 by its total outstanding shares 573886283 (573.89 Million). Also see 600222 operating cash flow for how efficiently the company converts equity into cash flow.
Henan Taloph Pharmaceutical Stock Co Ltd Market Cap History (2015–2026)
Henan Taloph Pharmaceutical Stock Co Ltd market cap history from 2015 to 2026. Data shows change from $785.36 Million to $544.17 Million (-1.35% CAGR). Check 600222 share price today for real-time trading data and today's change.
Henan Taloph Pharmaceutical Stock Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Henan Taloph Pharmaceutical Stock Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Henan Taloph Pharmaceutical Stock Co Ltd (600222) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.31x
Henan Taloph Pharmaceutical Stock Co Ltd's market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.21x
Henan Taloph Pharmaceutical Stock Co Ltd's market cap is 9.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $699.39 Million | $953.31 Million | $4.02 Million | 0.73x | 174.17x |
| 2017 | $444.01 Million | $1.17 Billion | $5.13 Million | 0.38x | 86.60x |
| 2018 | $284.30 Million | $1.19 Billion | -$115.32 Million | 0.24x | N/A |
| 2019 | $382.12 Million | $1.31 Billion | $44.41 Million | 0.29x | 8.60x |
| 2020 | $418.91 Million | $1.42 Billion | $29.24 Million | 0.30x | 14.33x |
| 2021 | $752.82 Million | $1.60 Billion | $6.00 Million | 0.47x | 125.57x |
| 2022 | $534.94 Million | $1.96 Billion | -$72.20 Million | 0.27x | N/A |
| 2023 | $514.78 Million | $2.07 Billion | $43.56 Million | 0.25x | 11.82x |
| 2024 | $427.45 Million | $1.94 Billion | $50.53 Million | 0.22x | 8.46x |
| 2025 | $552.57 Million | $1.76 Billion | $60.00 Million | 0.31x | 9.21x |
Competitor Companies of 600222 by Market Capitalization
Companies near Henan Taloph Pharmaceutical Stock Co Ltd in the global market cap rankings as of November 8, 2026. Also see Henan Taloph Pharmaceutical Stock Co Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Henan Taloph Pharmaceutical Stock Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Henan Taloph Pharmaceutical Stock Co Ltd (2015–2026)
Market capitalization of Henan Taloph Pharmaceutical Stock Co Ltd from 2015 to today. Between 2015 and today, Henan Taloph Pharmaceutical Stock Co Ltd's market cap moved from $785.36 Million to $ 544.17 Million, with a yearly change of -1.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥544.17 Million | -1.52% |
| 2025 | CN¥552.57 Million | +29.27% |
| 2024 | CN¥427.45 Million | -16.97% |
| 2023 | CN¥514.78 Million | -3.77% |
| 2022 | CN¥534.94 Million | -28.94% |
| 2021 | CN¥752.82 Million | +79.71% |
| 2020 | CN¥418.91 Million | +9.63% |
| 2019 | CN¥382.12 Million | +34.41% |
| 2018 | CN¥284.30 Million | -35.97% |
| 2017 | CN¥444.01 Million | -36.52% |
| 2016 | CN¥699.39 Million | -10.95% |
| 2015 | CN¥785.36 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Henan Taloph Pharmaceutical Stock Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $544.17 Million USD |
| MoneyControl | $544.17 Million USD |
| MarketWatch | $544.17 Million USD |
| marketcap.company | $544.17 Million USD |
| Reuters | $544.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more